Introduction Biologics serve as a cornerstone in psoriasis treatment, with low disease activity
or sometimes even clinical remission as a realistic treatment outcome. So far, it is unclear …

With the arrival of biologics and the shift toward treat-to-target therapy, the possibility of a
sustained clinical response has become an achievable goal for many patients with …

Objective To provide the initial installment of a living guideline that will provide up-to-date
guidance on the pharmacological management of patients with rheumatoid arthritis (RA) in …

Patient preferences for rheumatoid arthritis treatment : Current Opinion in Rheumatology Patient
preferences for rheumatoid arthritis treatment : Current Opinion in Rheumatology Log in or …

Dose reduction of biologics for psoriasis could contribute to more efficient use of these
expensive medicines. Evidence on opinions of patients with psoriasis regarding dose …

Background About 20% of patients with rheumatoid arthritis on disease-modifying
antirheumatic drugs (DMARDs) can reach sustained DMARD-free remission. Nonetheless …

Objectives To understand the perspectives of patients and rheumatologists for tapering
DMARDs in RA. Methods Using semi-structured interview guides, we conducted individual …

Objectives Many patients with rheumatoid arthritis (RA) require treatment with tumour
necrosis factor inhibitor (TNFi) to reach remission. It is debated whether tapering of TNFi to …

Background Biological disease-modifying antirheumatic drugs (bDMARDs) are effective in
the treatment of rheumatoid arthritis. However, as bDMARDs may also lead to adverse …

Objective In patients with rheumatoid arthritis (RA) in sustained remission, tapering of
biological disease-modifying anti-rheumatic drugs can be considered. Tapering has already …